Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in

Alvita Vilkeviciute, Dzastina Cebatoriene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alvita VilkeviciuteNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.ORCID 0000-0002-0427-5568

Dzastina CebatorieneMedical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus St. 9, LT-44307 Kaunas, Lithuania.

Loresa KriauciunieneNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.

Dalia ZaliunieneDepartment of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.

Rasa LiutkevicieneNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.

Funding

The Research Council of Lithuania under the initiative of Researcher Group Projects. S-MIP-23-96

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a progressive neurodegenerative condition leading to vision loss and eventual blindness, with exudative AMD posing a heightened risk due to choroidal neovascularization and localized edema. Therapies targeting the VEGF pathway aim to address this mechanism for treatment effectiveness. Our study aimed to evaluate associations between specific genetic variants (

Indexed as

Collagen Type XInterleukin-10Interleukin-9Intracellular Signaling Peptides and ProteinsPolymorphism, Single NucleotideProtein Serine-Threonine KinasesVascular Endothelial Growth Factor AAgedAged, 80 and overCollagen Type VIIIDNA-Binding ProteinsFemaleGenotypeHumansMacular DegenerationMaleCOL10A1 protein, humanCol8A1 protein, humanCollagen Type VIIICollagen Type XDNA-Binding ProteinsIL10 protein, humanIL9 protein, humanInterleukin-10Interleukin-9Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesTRIB1 protein, humanVascular Endothelial Growth Factor AVEGFA protein, humanage-related macular degenerationanti-VEGFA therapyELISAsingle-nucleotide variants

Identifiers

PMID38999967

DOI10.3390/ijms25136859

PMCPMC11241034

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.